CTOs on the Move

Quotient Sciences

www.seaviewresearch.net

 
Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Faraday Pharmaceuticals

Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.

Algorithme Pharma

Algorithme Pharma, Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

Confab Laboratories

Confab Laboratories Inc. is a Saint-Hubert, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.